ArticleIntestinal research2018

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.

Vandana Midha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.